Next Article in Journal
Combined Use of S. pombe and L. thermotolerans in Winemaking. Beneficial Effects Determined Through the Study of Wines’ Analytical Characteristics
Next Article in Special Issue
Lectin Digestibility and Stability of Elderberry Antioxidants to Heat Treatment In Vitro
Previous Article in Journal
Photochemically Immobilized 4-Methylbenzoyl Cellulose as a Powerful Chiral Stationary Phase for Enantioselective Chromatography
Previous Article in Special Issue
Ribosome-Inactivating Proteins from Plants: A Historical Overview
Open AccessArticle

DeBouganin Diabody Fusion Protein Overcomes Drug Resistance to ADCs Comprised of Anti-Microtubule Agents

Viventia Bio Inc., Winnipeg, MB R3T 3Z1, Canada
Avipep Pty Ltd., Parkville 3052, Victoria, Australia
Eleven Biotherapeutics, Philadelphia, PA 19104, USA
Eleven Biotherapeutics, Winnipeg, MB R3E 0W3, Canada
Author to whom correspondence should be addressed.
Academic Editor: Els Van Damme
Molecules 2016, 21(12), 1741;
Received: 15 October 2016 / Revised: 9 December 2016 / Accepted: 12 December 2016 / Published: 17 December 2016
Antibody drug conjugates (ADC), comprised of highly potent small molecule payloads chemically conjugated to a full-length antibody, represent a growing class of therapeutic agents. The targeting of cytotoxic payloads via the specificity and selectivity of the antibody has led to substantial clinical benefits. However, ADC potency can be altered by mechanisms of resistance such as overexpression of efflux pumps or anti-apoptotic proteins. DeBouganin is a de-immunized variant of bouganin, a ribosome-inactivating protein (RIP) that blocks protein synthesis, thereby leading to apoptosis. When conjugated to trastuzumab (T-deB), deBouganin was more potent than ado-trastuzumab-emtansine (T-DM1) and unaffected by resistance mechanisms to which DM1 is susceptible. To further highlight the differentiating mechanism of action of deBouganin, HCC1419 and BT-474 tumor cells that survived T-DM1 or trastuzumab-MMAE (T-MMAE) treatment were treated with an anti-HER2 C6.5 diabody–deBouganin fusion protein or T-deB. C6.5 diabody–deBouganin and T-deB were potent against HCC1419 and BT-474 cells that were resistant to T-DM1 or T-MMAE killing. The resistant phenotype involved MDR pumps, Bcl-2 family members, and the presence of additional unknown pathways. Overall, the data suggest that deBouganin is effective against tumor cell resistance mechanisms selected in response to ADCs composed of anti-microtubule payloads. View Full-Text
Keywords: immunotoxin; deBouganin; ribosome inactivating protein; HER2; C6.5 diabody immunotoxin; deBouganin; ribosome inactivating protein; HER2; C6.5 diabody
Show Figures

Figure 1

MDPI and ACS Style

Chooniedass, S.; Dillon, R.L.; Premsukh, A.; Hudson, P.J.; Adams, G.P.; MacDonald, G.C.; Cizeau, J. DeBouganin Diabody Fusion Protein Overcomes Drug Resistance to ADCs Comprised of Anti-Microtubule Agents. Molecules 2016, 21, 1741.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop